Cloning and functional expression of a human glucagon-like peptide-1 receptor
Data on the long-term efficacy of oral semaglutide for the significant reduction in MACEs are expected, as clinical studies are already being conducted
Patients should not discontinue necessary bone-protective treatments due to concerns about GLP-1 therapy
New Formulations: Efforts are underway to create more convenient formulations, including longer-acting injectables that may only require monthly administration and improved oral versions
J Affect Disord 15(369):922927 [DOI] [PubMed] [Google Scholar] 84.Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C (2024) Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
In addition to GLP-1/GIP/GCG receptors tri-agonists, there are also triagonists targeting Xenopus GLP-1/GCG/Cholecystokinin-2 (CCK2) receptors [107], GLP-1/GCG/ neuropeptide Y 2 receptors [108], and GLP-1R, neuropeptide Y1, and neuropeptide Y2 receptors [109]